HRP20141170T1 - Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe - Google Patents
Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe Download PDFInfo
- Publication number
- HRP20141170T1 HRP20141170T1 HRP20141170AT HRP20141170T HRP20141170T1 HR P20141170 T1 HRP20141170 T1 HR P20141170T1 HR P20141170A T HRP20141170A T HR P20141170AT HR P20141170 T HRP20141170 T HR P20141170T HR P20141170 T1 HRP20141170 T1 HR P20141170T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- cell
- human
- drug conjugate
- expressing
- Prior art date
Links
- 101100460850 Homo sapiens NCR3LG1 gene Proteins 0.000 claims 16
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 239000000611 antibody drug conjugate Substances 0.000 claims 10
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 10
- 210000004408 hybridoma Anatomy 0.000 claims 9
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 229930190007 Baccatin Chemical class 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 229930188224 Cryptophycin Natural products 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 108010006226 cryptophycin Proteins 0.000 claims 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical class CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 102000052554 human NCR3 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- -1 vinca alkaloids Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (26)
1. Izolirano monoklonsko antitijelo, naznačeno time, što kompetira za vezanje za vanstaničnu domenu humanog B7H6, pokazano aminokiselinskim reziduama 25-266 SEQ ID NO:2, sa antitijelom proizvedenim hibridomom odabranim iz grupe koja se sastoji od:
a) hibridoma klonske oznake broj 4E5.5, deponiranog kao Depozit Br. CNCM I-4242; i
b) hibridoma klonske oznake broj 17B1.3, deponiranog kao Depozit Br. CNCM I-4245
pri čemu monoklonsko antitijelo inhibira interakciju humanog B7H6 sa humanim NKp30 i inhibira stanično prepoznavanje ciljnih stanica koje eksprimiraju B7H6.
2. Antitijelo iz Zahtjeva 1, naznačeno time, što se spomenuto antitijelo bira iz grupe koja se sastoji od mišjeg antitijela, himernog antitijela, humaniziranog antitijela i humanog antitijela.
3. Antitijelo iz Zahtjeva 1, naznačeno time, što je spomenuto antitijelo mišje antitijelo odabrano iz grupe koja se sastoji od:
a) antitijela proizvedenog hibridomom klonske oznake broj 4E5.5, deponiranog kao Depozit Br. CNCM I-4242 ili njegovog antigen-vežućeg fragmenta; i
b) antitijela proizvedenog hibridomom klonske oznake broj 17B1.3, deponiranog kao Depozit Br. CNCM I-4245 ili njegovog antigen-vežućeg fragmenta.
4. Antitijelo iz Zahtjeva 1, naznačeno time, što je spomenuto antitijelo humanizirano antitijelo izvedeno iz antitijela odabranog iz grupe koja se sastoji od:
a) antitijela proizvedenog hibridomom klonske oznake broj 4E5.5, deponiranog kao Depozit Br. CNCM I-4242; i
b) antitijela proizvedenog hibridomom klonske oznake broj 17B1.3, deponiranog kao Depozit Br. CNCM I-4245.
5. Antitijelo iz Zahtjeva 1 ili 4, naznačeno time, što je spomenuto antitijelo jednolančano antitijelo.
6. Antitijelo iz bilo kojeg od Zahtjeva 1, 2 i 4, naznačeno time, što spomenuto antitijelo sadrži Fc regiju sa najmanje jednom od ADCC aktivnosti i CDC aktivnosti.
7. Antitijelo prema Zahtjevu 6, naznačeno time, što je Fc regija jednolančani Fc (scFc).
8. Dijagnostički kit, naznačen time, što sadrži antitijelo iz bilo kojeg od Zahtjeva 1 do 7; i služi za detektiranje vezanja tim antitijelom.
9. Konjugat antitijelo-lijek, naznačen time, što sadrži monoklonsko antitijelo prema bilo kojem od Zahtjeva 1-7, pri čemu je antitijelo konjugirano sa citotoksičnim sredstvom.
10. Konjugat antitijelo-lijek iz Zahtjeva 9, naznačen time, što se citotoksično sredstvo bira iz grupe koja se sastoji od antitubulinskog sredstva, sredstva koja se veže za mali žlijeb DNK, alkilirajućeg sredstva malog žlijeba DNK, duokarmicina i puromicina.
11. Konjugat antitijelo-lijek iz Zahtjeva 10, naznačen time, što se antitubulinsko sredstvo bira iz grupe koja se sastoji od dolastatina, alkaloida vinke, podofilotoksina, taksana, bakatinskog derivata, kriptoficina, majtanzinoida i kombretastatina.
12. Konjugat antitijelo-lijek iz Zahtjeva 9, naznačen time, što je antitijelo preko linkera konjugirano sa citotoksičnim sredstvom.
13. Konjugat antitijelo-lijek iz Zahtjeva 12, naznačen time, što se linker odsjeca pod uvjetima koji vladaju unutar stanice.
14. Konjugat antitijelo-lijek iz Zahtjeva 13, naznačen time, što je linker koji se odsjeca peptidni linker koji se odsjeca unutarstaničnom proteazom.
15. Smjesa, naznačena time, što sadrži antitijelo iz bilo kojeg od Zahtjeva 1-7, ili konjugat antitijelo-lijek iz bilo kojeg od Zahtjeva 9 -14; i farmaceutski prihvatljivi nosač.
16. In vitro metoda za smanjenje aktivnosti humane stamoce prirodnog ubojice (NK) prema stanici koja eksprimira humani B7H6, naznačena time, što metoda uključuje dovođenje u kontakt stanice koja eksprimira humani B7H6, u prisustvu humane NK stanice, sa efikasnom količinom monoklonskog antitijela prema bilo kojem od Zahtjeva 1-7.
17. In vitro metoda iscrpljivanja ili inhibiranja rasta B7H6-eksprimirajućih stanice unutar populacije stanica koja sadrži spomenute B7H6-eksprimirajuće stanice, naznačena time, što metoda uključuje dovođenje u kontakt spomenutih B7H6-eksprimirajućih stanica sa efikasnom količinom konjugata antitijelo-lijek prema bilo kojem od Zahtjeva 9-14.
18. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 9-14, naznačen time, što se uporabljuje za liječenje B7H6-eksprimirajućeg kancera kod subjekta.
19. Monoklonsko antitijelo prema bilo kojem, od Zahtjeva 1-7, naznačeno time, što se uporabljuje za liječenje B7H6-eksprimirajućeg kancera kod subjekta.
20. Konjugat antitijelo-lijek za uporabu prema Zahtjevu 18 ili antitijelo za uporabu prema Zahtjevu 19, naznačen time, što je kancer koji eksprimira B7H6 kancer kolona, jetre, cerviksa, pluća, pankreasa ili prostate, ili što je kancer koji eksprimira B7H6 prohemocitna leukemija, limfom B stanica, limfom T stanica, monocitni limfom, eritroleukemija, Burkitt-ov limfom, i kronična mijelogena leukemija ili akutna limfoblastna leukemija.
21. In vitro metoda detektiranja stanične ekspresije B7H6, naznačena time, što uključuje:
(1) dovođenje u kontakt biološkog uzorka koji sadrži humanu stanicu koja se testira sa monoklonskim antitijelom prema bilo kojem od Zahtjeva 1-7; i
(2) detektiranje vezanja spomenutog antitijela;
pri čemu vezanje spomenutog antitijela ukazuje na prisustvo B7H6 na stanici, čime se detektira da li stanica eksprimira B7H6.
22. In vitro metoda iz Zahtjeva 21, naznačena time, što biološki uzorak sadrži intaktne humane stanice, ili pri čemu biološki uzorak sadrži membransku frakciju stanice koju treba testirati.
23. In vitro metoda iz Zahtjeva 21 ili 22, naznačena time, što je antitijelo obilježeno detektabilnim obilježivačem odabranim iz grupe koja se sastoji od radioizotopa,fluorescentnog obilježivača, hemiluminiscentnog obilježivača, enzimskog obilježivača i bioluminiscentnog obilježivača.
24. Monoklonsko antitijelo prema bilo kojem, od Zahtjeva 1-7, naznačeno time, što se koristi za dijagnosticiranje kancera koji eksprimira B7H6, kod subjekta, pri čemu su spomenuta monoklonska antitijela konjugirana sa detektabilnim obilježivačem.
25. Monoklonsko antitijelo za uporabu prema Zahtjevu 24, naznačeno time, što kancer je kancer kolona, jetre, cerviksa, pluća. pankreasa ili prostate.
26. Stanica koja proizvodi antitijelo, naznačena time, što se bira iz grupe koja se sastoji od:
a) hibridoma klonske oznake broj 4E5.5, depiranog kao Depozit Br. CNCM I-4242; i
b) hibridoma klonske oznake broj 17B1.3 deponiranog kao Depozit Br. CNCM I-4245.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28501809P | 2009-12-09 | 2009-12-09 | |
EP10813116.0A EP2510011B2 (en) | 2009-12-09 | 2010-12-08 | Monoclonal antibodies that bind b7h6 and uses thereof |
PCT/IB2010/003411 WO2011070443A1 (en) | 2009-12-09 | 2010-12-08 | Monoclonal antibodies that bind b7h6 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20141170T1 true HRP20141170T1 (hr) | 2015-01-30 |
Family
ID=43827827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20141170AT HRP20141170T1 (hr) | 2009-12-09 | 2014-12-02 | Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe |
Country Status (18)
Country | Link |
---|---|
US (2) | US8822652B2 (hr) |
EP (1) | EP2510011B2 (hr) |
JP (2) | JP2013513380A (hr) |
CN (2) | CN104926942B (hr) |
BR (1) | BR112012013975B8 (hr) |
CA (1) | CA2783740C (hr) |
DK (1) | DK2510011T3 (hr) |
EA (1) | EA024629B1 (hr) |
ES (1) | ES2523472T3 (hr) |
HR (1) | HRP20141170T1 (hr) |
IN (1) | IN2012DN04908A (hr) |
MX (1) | MX2012006443A (hr) |
PL (1) | PL2510011T3 (hr) |
PT (1) | PT2510011E (hr) |
RS (1) | RS53667B1 (hr) |
SI (1) | SI2510011T1 (hr) |
SM (1) | SMT201400184B (hr) |
WO (1) | WO2011070443A1 (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
JP2013513380A (ja) | 2009-12-09 | 2013-04-22 | アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・(イ・エヌ・エス・ウ・エール・エム) | B7h6と結合するモノクローナル抗体およびその使用 |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
JP2014534165A (ja) * | 2011-09-13 | 2014-12-18 | ドイチェス クレブスフォルシュンクスツェントルム | B7−h6ポリペプチドに対するb7−h6治療活性モノクローナル抗体 |
EP2847223B1 (en) * | 2012-05-07 | 2019-03-27 | Trustees of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
WO2014044799A1 (en) * | 2012-09-21 | 2014-03-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides |
EP2711707A1 (en) | 2012-09-21 | 2014-03-26 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to chemotherapy |
CN109310764B (zh) * | 2016-04-15 | 2022-01-14 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
EP3469001A4 (en) * | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS |
EP3710481A4 (en) * | 2017-11-16 | 2021-08-18 | Antigenesis LLC | LYSOSOME-INDUCED IMMUNOGENIC CELL DEATH SYSTEMS AND PROCEDURES |
KR20220151164A (ko) * | 2020-01-17 | 2022-11-14 | 베이진 엘티디 | 항-NKp30 항체 및 이용 방법 |
CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
CN114395044B (zh) * | 2021-12-07 | 2023-12-29 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
KR20240003756A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | NKp30 결합력이 향상된 B7-H6 변이체 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4883662A (en) | 1984-04-10 | 1989-11-28 | Clinical Biotechnologies, Inc. | Method of increasing natural killer cell population of cancer patients |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5082833A (en) | 1988-06-30 | 1992-01-21 | Shamsuddin Abulkalam M | Reduction of cell proliferation and enhancement of nk-cell activity |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6239104B1 (en) | 1997-02-25 | 2001-05-29 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
AU2769101A (en) * | 2000-01-07 | 2001-07-24 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
WO2004022594A2 (en) * | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
CA2606867A1 (en) * | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Methods of using pnkp30, a member of the b7 family, to modulate the immune system |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
CA2697992C (en) | 2007-10-04 | 2017-08-22 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
JP2013513380A (ja) | 2009-12-09 | 2013-04-22 | アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・(イ・エヌ・エス・ウ・エール・エム) | B7h6と結合するモノクローナル抗体およびその使用 |
-
2010
- 2010-12-08 JP JP2012542637A patent/JP2013513380A/ja not_active Ceased
- 2010-12-08 ES ES10813116.0T patent/ES2523472T3/es active Active
- 2010-12-08 CA CA2783740A patent/CA2783740C/en active Active
- 2010-12-08 MX MX2012006443A patent/MX2012006443A/es active IP Right Grant
- 2010-12-08 PT PT108131160T patent/PT2510011E/pt unknown
- 2010-12-08 WO PCT/IB2010/003411 patent/WO2011070443A1/en active Application Filing
- 2010-12-08 EP EP10813116.0A patent/EP2510011B2/en active Active
- 2010-12-08 RS RS20140657A patent/RS53667B1/en unknown
- 2010-12-08 US US13/515,276 patent/US8822652B2/en active Active
- 2010-12-08 BR BR112012013975A patent/BR112012013975B8/pt active IP Right Grant
- 2010-12-08 CN CN201510169548.3A patent/CN104926942B/zh active Active
- 2010-12-08 EA EA201270654A patent/EA024629B1/ru not_active IP Right Cessation
- 2010-12-08 PL PL10813116T patent/PL2510011T3/pl unknown
- 2010-12-08 IN IN4908DEN2012 patent/IN2012DN04908A/en unknown
- 2010-12-08 DK DK10813116.0T patent/DK2510011T3/en active
- 2010-12-08 SI SI201030801T patent/SI2510011T1/sl unknown
- 2010-12-08 CN CN201080063065.0A patent/CN102741290B/zh active Active
-
2014
- 2014-08-04 US US14/450,921 patent/US9663577B2/en active Active
- 2014-12-02 HR HRP20141170AT patent/HRP20141170T1/hr unknown
- 2014-12-11 SM SM201400184T patent/SMT201400184B/xx unknown
-
2016
- 2016-07-29 JP JP2016149287A patent/JP6212181B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017031147A (ja) | 2017-02-09 |
EP2510011B1 (en) | 2014-09-17 |
SMT201400184B (it) | 2015-01-15 |
US9663577B2 (en) | 2017-05-30 |
US20150056214A1 (en) | 2015-02-26 |
MX2012006443A (es) | 2012-06-28 |
US8822652B2 (en) | 2014-09-02 |
CN102741290B (zh) | 2015-04-22 |
RS53667B1 (en) | 2015-04-30 |
EA024629B1 (ru) | 2016-10-31 |
IN2012DN04908A (hr) | 2015-09-25 |
SI2510011T1 (sl) | 2014-12-31 |
JP6212181B2 (ja) | 2017-10-11 |
EP2510011B2 (en) | 2021-03-31 |
CN104926942B (zh) | 2018-09-14 |
US20130004432A1 (en) | 2013-01-03 |
CN102741290A (zh) | 2012-10-17 |
ES2523472T3 (es) | 2014-11-26 |
CA2783740C (en) | 2020-03-10 |
CA2783740A1 (en) | 2011-06-16 |
BR112012013975A2 (pt) | 2017-01-10 |
EP2510011A1 (en) | 2012-10-17 |
DK2510011T3 (en) | 2014-12-01 |
PT2510011E (pt) | 2014-12-12 |
EA201270654A1 (ru) | 2013-02-28 |
CN104926942A (zh) | 2015-09-23 |
JP2013513380A (ja) | 2013-04-22 |
PL2510011T3 (pl) | 2015-02-27 |
WO2011070443A1 (en) | 2011-06-16 |
BR112012013975B8 (pt) | 2021-05-25 |
BR112012013975B1 (pt) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20141170T1 (hr) | Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe | |
JP2013513380A5 (hr) | ||
CA2827637C (en) | Novel modulators and methods of use | |
AU2011295715B9 (en) | Novel modulators and methods of use | |
AU2011360938B2 (en) | Novel modulators and methods of use | |
AU2011293127B2 (en) | Notum protein modulators and methods of use | |
WO2016118090A1 (en) | Cancer specific antigen-binding proteins | |
WO2013126746A2 (en) | Novel modulators and methods of use | |
JP2016538318A (ja) | 新規sez6モジュレーターおよび使用方法 | |
US11353458B2 (en) | Prognostic method | |
TW201136608A (en) | Novel humanized anti CXCR4 antibodies for the treatment of cancer | |
US20180142032A1 (en) | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof | |
US11555074B2 (en) | Monoclonal antibodies and conjugates against prostaglandin F2 receptor inhibitor and uses thereof | |
SAHIN et al. | Patent 2919570 Summary | |
NZ615285B2 (en) | Novel modulators and methods of use |